A Bob Langer-affiliated startup has collected a megaround to advance at least three experimental oligonucleotide medicines.
Soufflé Therapeutics uncorked a fresh
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.